National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.


NCPE Assessment Process Complete
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended


Following an amendment of the product license by the EMA, a new rapid review was commissioned by the HSE.
Rapid review commissioned 21/06/2018
Rapid review received 10/07/2018
Rapid review completed 27/07/2018
Rapid Review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that pembrolizumab not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.